ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Incomplete Penetrance in Autoinflammatory Diseases

Michael Cammarata, MD, RhMSUS  |  November 1, 2025

He acknowledged that ascertainment and reporting bias likely play a role because patients without disease manifestation won’t come to attention, thus he suspects this phenomenon is significantly under-identified.

Introducing Monoallelic Expression

Dr. Bogunovic noted several mechanisms by which genes are not expressed from both alleles—genomic imprinting, X-inactivation, transcriptional bursting and the focus of this talk, monoallelic expression.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To explain MAE, he explained that all cells have a paternal and maternal allele, meaning genetically they are heterozygous. However, somewhere during development, the cell commits to propagation of either the maternal or paternal allele. This commitment is stable through mitosis and only expressed in a single cell type, such as T cells. Merging the concepts of MAE and incomplete penetrance, he demonstrated a pedigree whereby a mother, father and son all carried a mutation. The son had fully penetrant disease, the father had partial expressivity and the mother did not express disease. The healthy mother dominantly expressed the healthy allele, and the father skewed toward mutant expression.

Dr. Bogunovic explained that the origin of this concept came from studying a patient from New York with immune dysregulation, found to have a de novo mutation in Janus kinase 1 (JAK1), which is downstream to more than 25 different cytokines. Single-cell RNA sequencing on JAK1 surprisingly found that 50% of cells only expressed the mutant allele and not the wild-type allele. This deviated from the traditional dogma that JAK1 should be fully expressed in a biallelic pattern. These findings led to the hypothesis that monoallelic expression can lead to phenotypic variability in IEIs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Excited by this possibility, Dr. Bogunovic and his team decided to take peripheral blood mononuclear cells (PBMCs) from 10 healthy donors in New York, sorted the cells into T cells, made large populations of T cell clones and validated a mechanism to determine if allelic bias was somatically acquired and stable. Using this clonal population, the team found evidence of MAE in IEI genes (e.g., JAK1, STAT1, NFKB1) even in healthy individuals. They found that about 5% of all genes and about 4% of IEI genes undergo MAE.

To validate their findings, the team examined JAK1 MAE via digital droplet polymerase chain reaction (PCR) for six different clones, as well as for a heterozygous variant in PLCG2 from one of the ten donors, repeating what they saw in RNA sequencing. Importantly, they found that PLCG2 MAE is stable in clones cultured over weeks.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2025geneticsinborn errors of immunitymonoallelic expressionResearch

Related Articles
    Stmool / shutterstock.com

    How to Avoid Cognitive Errors in Rheumatology

    March 14, 2022

    The 1999 Institute of Medicine report To Err Is Human gave a sobering depiction of the magnitude and consequences of medical error.1 The report concluded that approximately 98,000 people die in hospitals annually due to preventable medical errors. Of all the errors detailed in this report, diagnostic errors have since been determined to be the…

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

    Doest Rheumatoid Arthritis Take a Toll?

    November 15, 2013

    Exploring the Toll background

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences